You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 5,672,511

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,672,511

Title:	Base-modified enzymatic nucleic acid
Abstract:	Method to produce a more active ribozyme by introducing a modified base into a substrate binding arm of the ribozyme or its catalytic core.
Inventor(s):	Beigelman; Leonid (Longmont, CO), Karpeisky; Alex (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/437,114
Patent Claims:	1. An enzymatic nucleic acid molecule comprising at least one modified nucleotide, wherein base portion of said modified nucleotide is a 6-methyl uracil. 2. The enzymatic nucleic acid molecule of claim 1, wherein said nucleic acid is in a hammerhead configuration. 3. The enzymatic nucleic acid molecule of claim 1, wherein said nucleic acid is in a hairpin configuration. 4. The enzymatic nucleic acid molecule of claim 1, wherein said nucleic acid is in a hepatitis delta virus, group I intron, VS RNA or RNase P RNA configuration. 5. The enzymatic nucleic acid of any of claims 1-4, wherein said nucleic acid comprises: at least five ribose residues; at least three 5' terminal phosphorothioate linkages; position No. 4 of said nucleic acid is substituted with said 6-methyl uracil modification; and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications. 6. The enzymatic nucleic acid of any of claims 1-4, wherein said nucleic acid comprises: at least five ribose residues; at least three 5' terminal phosphorothioate linkages; position No. 7 of said nucleic acid is substituted with said 6-methyl uracil modification; and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications. 7. The enzymatic nucleic acid of any of claims 1-4, wherein said nucleic acid comprises: at least five ribose residues; at least three 5' terminal phosphorothioate linkages; position Nos. 4 and 7 of said nucleic acid is substituted with said 6-methyl uracil modification; and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications. 8. The enzymatic nucleic acid of any of claims 1-4, wherein said nucleic acid comprises: at least five ribose residues; position No. 4 of said nucleic acid is substituted with said 6-methyl uracil modification; and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications. 9. The enzymatic nucleic acid of any of claims 1-4, wherein said nucleic acid comprises: at least five ribose residues; position No. 7 of said nucleic acid is substituted with said 6-methyl uracil modification; and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications. 10. The enzymatic nucleic acid of any of claims 1-4, wherein said nucleic acid comprises: at least five ribose residues; position Nos. 4 and 7 of said nucleic acid is substituted with said 6methyl uracil modification; and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications. 11. The enzymatic nucleic acid of claim 2, wherein said nucleic acid comprises a stem II region of length greater than or equal to two base-pairs. 12. The enzymatic nucleic acid of claim 3, wherein said hairpin nucleic acid comprises a stem IV region of length greater than or equal to two base-pairs. 13. The enzymatic nucleic acid of claim 3, wherein said hairpin nucleic acid comprises a stem II region of length between three and seven base-pairs. 14. The enzymatic nucleic acid of any one of claims 1-4, wherein said nucleic acid comprises a 3'-cap structure. 15. The enzymatic nucleic acid of claim 1, wherein said 3'-cap is a 3'--3' linked inverted ribose. 16. A mammalian cell comprising the enzymatic nucleic acid of any one of claims 1-4, in vitro. 17. The mammalian cell of claim 16, wherein said cell is a human cell.

Details for Patent 5,672,511

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2014-09-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2014-09-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2014-09-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.